Abstract
The angiotensin II receptor antagonists (AIIRA) represent a new class of antihypertensive agents, with a mechanism of action that differs from that of other classes of antihypertensive agents that also affect the renin-angiotensin system (RAS), such as the angiotensin-converting enzyme (ACE) inhibitors. The AIIRA were developed to overcome several of the deficiencies of ACE inhibitors, which include the following: 1) competitive inhibition of the ACE enzyme results in a reactive increase in renin and angiotensin I (AI) levels, which may overcome the blockade; 2) ACE is a relatively nonspecific enzyme that has substrates in addition to AI, including bradykinin and other tachykinins; thus, inhibition of ACE may also result in accumulation of these substrates; 3) production of AII can occur through non-ACE pathways, in addition to being produced by the primary ACE pathway; these alternative pathways are unaffected by ACE inhibition; and 4) specific adverse effects are associated with inhibition of the ACE enzyme. This review summarizes the preclinical pharmacology of the AIIRA class of agents and describe the means by which the deficiencies associated with ACE inhibition are overcome. The specific characteristics of the new AIIRA ...Continue Reading
Citations
Jun 4, 1999·Journal of Clinical Pharmacology·M M McConnaugheyA J Ingenito
Jun 20, 2002·Journal of Cardiovascular Pharmacology·Maria R Marino, Nimish N Vachharajani
Jun 5, 2014·Medicinal Research Reviews·Mathias Hallberg
May 23, 2002·Journal of Hypertension·Helmy M SiragyRobert M Carey
Jan 20, 2006·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Eiichi GeshiTakashi Katagiri
Sep 12, 2000·Current Hypertension Reports·M E Fabiani, C I Johnston
Sep 12, 2000·American Journal of Hypertension·M E FabianiC I Johnston
Apr 9, 2004·Journal of Cardiovascular Pharmacology·Victor L SerebruanyCharles H Hennekens
Mar 24, 2017·Nutrients·Ceren Daskaya-DikmenBeraat Ozcelik
Aug 14, 2002·Journal of Clinical Pharmacy and Therapeutics·Y HaraK Hiwada
Sep 29, 2011·European Heart Journal·Thomas UngerDomenic A Sica
Jul 7, 2011·Expert Opinion on Pharmacotherapy·Jujhar Bains, William B Smith
Jan 11, 2013·International Journal of Hypertension·Hanna Andersson, Mathias Hallberg
Feb 12, 2004·Journal of Cardiovascular Pharmacology·Miho MizukamiIssei Komuro
Jun 11, 1999·Progress in Cardiovascular Diseases·G E SanderT D Giles
Feb 8, 2005·Cardiology Clinics·Kris Vijayaraghavan, Prakash C Deedwania
Oct 22, 2008·Cardiology Clinics·Usman Javed, Prakash C Deedwania
Jan 25, 2011·Cardiology Clinics·Krishnaswami Vijayaraghavan, Prakash Deedwania